Rutgers Cancer Institute Offers Clinical Trial Examining Potential Treatment for COVID-19

Combination of malaria drug and antibiotic being explored
Rutgers Cancer Institute of New Jersey

Newswise — New Brunswick, N.J., April 3, 2020 – Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is being offered at Rutgers Cancer Institute, Robert Wood Johnson University Hospital in New Brunswick, and University Hospital in Newark, is not limited to cancer patients.

There is no standard antiviral therapy approved by the Food and Drug Administration (FDA) for the treatment of people with COVID-19.  At present clinical management includes infection prevention, control measures and supportive care.  Researchers at Rutgers Cancer Institute are exploring if azithromycin combined with hydroxychloroquine is better than hydroxychloroquine alone for treatment of patients with COVID-19.  Azithromycin is approved by the FDA for the treatment of infections.  Hydroxychloroquine is approved by the FDA for the treatment of malaria and auto-immune diseases, such as lupus and rheumatoid arthritis.

“While some practitioners across the state have been offering this type of treatment for some individualized cases, it is imperative that a controlled clinical trial with a large patient population take place in order to ensure the integrity of the results being gathered. As a National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey has the infrastructure and expertise to carry out this clinical trial,” notes Rutgers Cancer Institute Director Steven K. Libutti, MD, FACS, who is also senior vice president, oncology services, RWJBarnabas Health and vice chancellor, cancer programs, Rutgers Biomedical and Health Sciences.

Patients aged 18 and older who are diagnosed with COVID-19 and meet other criteria may be eligible to participate. Prior to being accepted into the clinical trial, participants are required to undergo a number of tests including bloodwork and a physical exam. 

Eligible participants will be assigned randomly (by chance) into three groups:  1) azithromycin and hydroxychloroquine; 2) hydroxychloroquine alone; or 3) supportive care for 6 days followed by hydroxychloroquine.  Treatment will continue for 10 days. Once treatment is completed, participants will be followed monthly for six months to monitor for return of symptoms.

For information on how to take part in this clinical trial, individuals should call Rutgers Cancer Institute’s Office of Human Research Services at 732-235-7356 or email statewide_research@cinj.rutgers.edu.

About Rutgers Cancer Institute of New Jersey

As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery.  Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.

###

 




Filters close

Showing results

110 of 1987
access_time Embargo lifts in 2 days
Embargo will expire: 1-Jun-2020 11:00 AM EDT Released to reporters: 28-May-2020 5:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 1-Jun-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 28-May-2020 5:10 PM EDT
Mental health outcomes among health care workers during COVID-19 pandemic in Italy
JAMA - Journal of the American Medical Association

Symptoms of posttraumatic stress disorder, depression, anxiety and insomnia among health care workers in Italy during the COVID-19 pandemic are reported in this observational study.

Newswise: fimmu-11-01208-g001.jpg
Released: 28-May-2020 4:45 PM EDT
Genetics May Explain High COVID-19 Mortality in Italy, Inform Global Pandemic Response
Sbarro Health Research Organization (SHRO)

On March 11th 2020 the World Health Organization declared Coronavirus disease (COVID-19) a pandemic.

Released: 28-May-2020 3:55 PM EDT
Finding working capital is key to small businesses efforts as reopening accelerates
RAND Corporation

As small businesses reopen after a lengthy pandemic shutdown, one key challenge will be finding working capital to replenish inventories and pay employees until revenue returns to normal, according to a new RAND Corporation perspective based on interviews with a select group of small business owners.

Newswise: Leading Mindfully: COVID-19 and the Big Human Pivot, Part 3
Released: 28-May-2020 3:15 PM EDT
Leading Mindfully: COVID-19 and the Big Human Pivot, Part 3
University of Virginia Darden School of Business

If the COVID-19 crisis triggered health, economic, social and psychological changes that mean we will be living and working through destabilizing moments now and for the foreseeable future, then all the more reason now to adopt and practice essential skills of Leading Mindfully. How should we start thinking in new ways that better represent reality?

access_time Embargo lifts in 2 days
Embargo will expire: 1-Jun-2020 6:00 AM EDT Released to reporters: 28-May-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 1-Jun-2020 6:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 28-May-2020 2:40 PM EDT
Anesthesia Practices See Major Financial Hit as Physician Anesthesiologists Pivot During COVID-19 to Treat Patients in Critical Care and ICUs, ASA Survey Highlights
American Society of Anesthesiologists (ASA)

A recent survey of anesthesia administrators and executive members of the American Society of Anesthesiologists (ASA) finds a majority of physician anesthesiologists pivoted from working in the operating room to treating COVID-19 patients in critical care units and ICUs, making the most of their expertise in intubation, ventilation strategies, and critical care medicine, which includes all aspects of resuscitation with multiorgan failure.

Newswise: NC Economic Forecast: Recovery Could Take Years
Released: 28-May-2020 2:35 PM EDT
NC Economic Forecast: Recovery Could Take Years
University of North Carolina at Charlotte

John Connaughton, UNC Charlotte professor of financial economics, presents the quarterly Barings/UNC Charlotte NC Economic Forecast. In the forecast, he discussed the economic effects of COVID-19 and the outlook for the state's economic recovery.

Released: 28-May-2020 2:20 PM EDT
Kidney Health Initiative Urges the Acceleration of Home Therapy Technology in Response to Coronavirus 2019 (Covid-19)
American Society of Nephrology (ASN)

The COVID-19 pandemic highlights the vulnerability of people with kidney failure who rely on in-center hemodialysis. People with kidney failure are at high risk of severe COVID-19 complications and are exposed to infection due to a kidney replacement therapy process that requires traveling to a dialysis facility multiple times a week.


Showing results

110 of 1987

close
0.8356